Home  |  Contact

Cellosaurus HepG2S2 (CVCL_4W43)

[Text version]

Cell line name HepG2S2
Accession CVCL_4W43
Resource Identification Initiative To cite this cell line use: HepG2S2 (RRID:CVCL_4W43)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar).
Derived from sampling site: Liver.
Sequence variations Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
Disease Hepatoblastoma (NCIt: C3728)
Hepatoblastoma (ORDO: Orphanet_449)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0027 (Hep-G2)
Sex of cell Male
Age at sampling 15Y
Category Cancer cell line
Publications

PubMed=23111106; DOI=10.1016/j.canlet.2012.10.021
van Malenstein H., Dekervel J., Verslype C., Van Cutsem E., Windmolders P., Nevens F., van Pelt J.F.
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
Cancer Lett. 329:74-83(2013)

Cross-references
Other Wikidata; Q54882862
Entry history
Entry creation14-Dec-2015
Last entry update20-May-2021
Version number10